Matylda Resztak
Overview
Explore the profile of Matylda Resztak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abouzid M, Kruszyna L, Kerner J, Kagan L, Mikulska-Sauermann A, Filipowicz D, et al.
Biosci Rep
. 2025 Jan;
45(2).
PMID: 39873593
Roughly 90% of the Polish population experiences vitamin D deficiency. The 3-epi-25(OH)D2 and 3-epi-25(OH)D3 are stereoisomers of 25(OH)D2 and 25(OH)D3, and they can inadvertently be included in measurements of 25(OH)D...
2.
Liszka K, Marschollek P, Przystupski D, Fraczkiewicz J, Mielcarek-Siedziuk M, Olejnik I, et al.
J Fungi (Basel)
. 2025 Jan;
11(1).
PMID: 39852457
Introduction: Posaconazole is recommended for prophylaxis in pediatric immunocompromised patients. Due to its variability in bioavailability and drug-to-drug interactions, EBMT recommends regimens based on therapeutic drug monitoring (TDM). Materials And...
3.
Resztak M, Zalewska P, Wachowiak J, Sobkowiak-Sobierajska A, Glowka F
Eur J Clin Pharmacol
. 2024 Sep;
80(11):1829-1840.
PMID: 39240338
Purpose: Therapeutic drug monitoring (TDM) of voriconazole (VCZ) should be mandatory for all pediatric patients with invasive fungal infections (IFIs). The narrow therapeutic index, inter-individual variability in VCZ pharmacokinetics, and...
4.
Sobiak J, Resztak M, Sikora W, Zachwieja J, Ostalska-Nowicka D
Pharmacol Rep
. 2024 Jun;
76(4):910.
PMID: 38916851
No abstract available.
5.
Mikulska-Sauermann A, Resztak M, Karazniewicz-Lada M, Filipowicz D, Ruchala M, Glowka F
Nutrients
. 2024 Jun;
16(11).
PMID: 38892627
Hashimoto's thyroiditis (HT) is the leading cause of hypothyroidism, affecting mainly the female population. Many patients with HT have metabolic disorders and nutritional deficiencies. The aim of this study was...
6.
Sobiak J, Resztak M, Sikora W, Zachwieja J, Ostalska-Nowicka D
Pharmacol Rep
. 2024 Mar;
76(3):600-611.
PMID: 38485859
Background: Saliva sampling is one of the methods of therapeutic drug monitoring for mycophenolic acid (MPA) and its metabolite, mycophenolic acid glucuronide (MPAG). The study describes the liquid chromatography tandem...
7.
Sobiak J, Resztak M, Banasiak J, Zachwieja J, Ostalska-Nowicka D
Pharmacol Rep
. 2023 Mar;
75(3):726-736.
PMID: 36905501
Background: For therapeutic drug monitoring (TDM) of mycophenolic acid (MPA), which is frequently proposed, saliva might be a suitable and easy-to-obtain biological matrix. The study aimed to validate an HPLC...
8.
Sobiak J, Resztak M, Zachwieja J, Ostalska-Nowicka D
Clin Exp Pharmacol Physiol
. 2022 Jul;
49(11):1197-1208.
PMID: 35877984
Some studies have shown that the area under the concentration-time curve (AUC) of mycophenolic acid (MPA) should be higher for children with nephrotic syndrome (NS) than after renal transplantation. The...
9.
Resztak M, Sobiak J, Czyrski A
Pharmaceutics
. 2021 Dec;
13(12).
PMID: 34959272
The review includes studies dated 2011-2021 presenting the newest information on voriconazole (VCZ), mycophenolic acid (MPA), and vancomycin (VAN) therapeutic drug monitoring (TDM) in children. The need of TDM in...
10.
Czyrski A, Resztak M, Swiderski P, Brylak J, Glowka F
Pharmaceutics
. 2021 Nov;
13(11).
PMID: 34834376
Second generation triazoles are widely used as first-line drugs for the treatment of invasive fungal infections, including aspergillosis and candidiasis. This class, along with itraconazole, voriconazole, posaconazole, and isavuconazole, is...